Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-01-02
2007-01-02
Ewoldt, G. R. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S139100, C424S141100, C424S145100, C530S387300, C530S387900, C530S388250
Reexamination Certificate
active
10791619
ABSTRACT:
The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.
REFERENCES:
patent: 4255519 (1981-03-01), Terada et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5534617 (1996-07-01), Cunningham et al.
patent: 5561053 (1996-10-01), Crowley
patent: 5622700 (1997-04-01), Jardieu et al.
patent: 5705154 (1998-01-01), Dalie et al.
patent: 5750373 (1998-05-01), Garrard et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5965709 (1999-10-01), Presta et al.
patent: 5994511 (1999-11-01), Lowman et al.
patent: 6037453 (2000-03-01), Jardieu et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6329509 (2001-12-01), Jardieu et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 239 400 (1994-08-01), None
patent: WO 92/17207 (1992-10-01), None
patent: WO 93/04173 (1993-03-01), None
patent: WO 9311161 (1993-06-01), None
patent: WO 93/16185 (1993-08-01), None
patent: WO 94/20533 (1994-09-01), None
patent: WO 95/24481 (1995-09-01), None
patent: WO 97/06822 (1997-02-01), None
Chang, T W. “The pharmacological basis of anti-IgE therapy” (2000) Nature Biotechnology, 18:157-162.
Tortora et al., “Microbiology, an Introduction” 5thedition, (1995) Benjamin-Cummings Publishing Company, Inc., pp. 466-469.
Kipriyanov et al., “Generation of recombinant antibodies” (1999) Molecular Biotechnology, 12:173-201.
Leung et al., N Engl J Med, 2003, 348:986-993.
Webster's New World Dictionary, third college edition, 1988, Simon & Schuster, Inc., p. 1067.
Wadee et al., J Allergy Clin Immunol, 1987, 80:695-698.
Reimers et al., Clin Exp Allergy, 2000, 30:276-82.
Alberts et al., “The Immune System”Molecular Biology of The Cell, 3d edition, New York and London:Garland Publishing, Inc., Chapter 23, pp. G-15 and 1232, 1994.
Amit et al., “Three-Dimensional Structure of an Antigen-antibody Complex at 2.8 A Resolution”Science233:747-753 (Aug. 1986).
Barbas III et al., “In Vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity.”Proc. Natl. Acad. Sci. USA91(9):3809-3813 (Apr. 26, 1994).
Brennan et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1fragments”Science229:81-83 (Jul. 1985).
Cacia et al., “Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity”Biochemistry35(6):1897-1903 (Feb. 13, 1996).
Carter et al., “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment.”Bio/Technology. 10(2):163-167 (Feb. 1992).
Carter et al., “Humanization of an Anti-p185HER2Antibody For Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89:4285-4289 (May 1992).
Champe et al., “Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a”Journal of Biological Chemistry270:1388-1394 (1995).
Chothia and Lesk, “Canonical Structures for the Hypervariable Regions of Immunoglobins”J. Mol. Biol.196:901-917 (1987).
Chothia et al., “Domain Association in Immunoglobulin Molecules. The Packing of Variable Domains”Journal of Molecular Biology186:651-663 (1985).
Chothia, C. et al., “Conformations of immunoglobin hypervariable regions”Nature342(6252):877-883 (1989).
Clackson et al., “Making Antibody Fragments Using Phage Display Libraries”Nature352:624-628 (1991).
Co et al., “Humanized antibodies for antiviral therapy”Proc. Natl. Acad. Sci. USA88:2869-2873 (Apr. 1991).
Cunningham et al., “Production of an Atrial Natriuretic Peptide Variant that is Specific for Type A Receptor”EMBO Journal13(11):2508-2515 (1994).
Geiger and Clarke, “Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation”Journal of Biological Chemistry262(2):785-794 (Jan. 15, 1987).
Goding, J.W., “Conjugation of antibodies with fluorochromes: modifications to the standard methods”Journal of Immunological Methods13(3-4):215-226 (1976).
Hakimi et al., “The α subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding”Journal of Biological Chemistry265(336):22079-22081 (1990).
Hawkins et al., “Selection of Phage antibodies by Binding Affinity Mimicking Affinity Maturation”J. Mol. Biol, 226:889-896 (1992).
Herbert et al.Directory of Immunology, 3rd edition, Blackwell Scientific Publications pp. 77 (1985).
Holliger et al., ““Diabodies”: Small Bivalent and Bispecific Antibody Fragments.”Proc. Natl. Acad. Sci. USA90:6444-6448 (Jul. 1993).
Jones et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse.”Nature, 321:522-525 (May 29, 1986).
Kabat et al.Sequences of Proteins of Immunological Interest, Bethesda, MD:National Institute of Health (1987).
KabatSequences of Proteins of Immunological Interest(Fourth Ed:), 4th edition pp. 41-42, 167-168 (1987).
KabatSequences of Proteins of Immunological Interest(pp. 662-663, 671-672, 680-681, 697, 701-702, 710, 719-720, 2275-2276), 5th edition'1 (1991).
Kettleborough et al., “Humanization of a Mouse Monoclonal Antibody by CDR-grafting: the Importance of Framework Residues on Loop Conformation”Protein Engineering4(7):773-783 (1991).
Kohler and Milstein., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity.”Nature, 256:495-497 (Aug. 7, 1975).
Konig et al., “Chemical and Biological Properties of Porcine Secretin and Secretin Analogues Modified in Positions 3 and 4”Gastroenterology72:797-800 (1977).
Kunkel et al., “Efficient site-directed mutagenesis using uracil-containing DNA”Methods in Enzymology204:125-139 (1991).
Lowe et al., “Allergen-induced Histamine Release in Rat Mast Cells Transfected with the α Subunits of FcεRI”J. Immunological Methods184:113-122 (1995).
Lowenson and Clarke, “Identification of isoaspartyl-containing sequences in peptides and proteins that are unusually poor substrates for the class II protein carboxyl methyltransferase”Journal of Biological Chemistry265(6):3106-3110 (Feb. 25, 1990).
Lowman and Wells, “Affinity Maturation of Human Growth Hormone by Monovalent Phage Display”J. Mol. Biol. 234:564-578 (1993).
Lowman et al., “Selecting High-Affinity Binding Proteins by Monovalent Phage Display”Biochemistry30(45):10832-10838 (1991).
Marks et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling”Bio/Technology10:779-783 (1992).
Marks et al., “By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage”J. Mol. Biol.222:581-597 (1991).
McCafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains”Nature348:552-554 (1990).
Metzger and Kinet, “How Antibodies Work: Focus on Fc Receptors”FASEB J2(1):3-11 (Jan.
Jardieu Paula M.
Lowe John
Lowman Henry B.
Presta Leonard G.
Ewoldt G. R.
Genentech Inc.
Svoboda Craig G.
Szperka Michael
LandOfFree
Method for treating IgE-mediated disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating IgE-mediated disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating IgE-mediated disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3757849